Grunenthal Agrees US$ 922 m Deal With AstraZeneca for Nexium a...
AACHEN, Germany, October 30, 2018 /PRNewswire-AsiaNet/ -- - Biggest single investment in Gruenenthal's history that will significantly strengthen the company's leading position in pain management- Gastroprotective therapies to address a high unmet medical need[1] in pain patients on non-steroidal...
Read more https://view-release/?pr-id=76029